首页> 美国卫生研究院文献>Scientific Reports >A potential prognostic long non-coding RNA signature to predict metastasis-free survival of breast cancer patients
【2h】

A potential prognostic long non-coding RNA signature to predict metastasis-free survival of breast cancer patients

机译:潜在的长时非编码RNA预后物可预测乳腺癌患者的无转移生存

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Long non-coding RNAs (lncRNAs) have been implicated in a variety of biological processes, and dysregulated lncRNAs have demonstrated potential roles as biomarkers and therapeutic targets for cancer prognosis and treatment. In this study, by repurposing microarray probes, we analyzed lncRNA expression profiles of 916 breast cancer patients from the Gene Expression Omnibus (GEO). Nine lncRNAs were identified to be significantly associated with metastasis-free survival (MFS) in the training dataset of 254 patients using the Cox proportional hazards regression model. These nine lncRNAs were then combined to form a single prognostic signature for predicting metastatic risk in breast cancer patients that was able to classify patients in the training dataset into high- and low-risk subgroups with significantly different MFSs (median 2.4 years versus 3.0 years, log-rank test p < 0.001). This nine-lncRNA signature was similarly effective for prognosis in a testing dataset and two independent datasets. Further analysis showed that the predictive ability of the signature was independent of clinical variables, including age, ER status, ESR1 status and ERBB2 status. Our results indicated that lncRNA signature could be a useful prognostic marker to predict metastatic risk in breast cancer patients and may improve upon our understanding of the molecular mechanisms underlying breast cancer metastasis.
机译:长期的非编码RNA(lncRNA)已牵涉到各种生物学过程中,失调的lncRNA已显示出潜在的作用,可作为生物标志物以及癌症预后和治疗的治疗靶标。在这项研究中,通过使用微阵列探针,我们分析了来自Gene Expression Omnibus(GEO)的916名乳腺癌患者的lncRNA表达谱。使用Cox比例风险回归模型,在254名患者的训练数据集中,九个lncRNA被确定与无转移生存(MFS)显着相关。然后将这9个lncRNA组合在一起,以形成预测乳腺癌患者转移风险的单一预后特征,从而能够将训练数据集中的患者分为MFS明显不同的高风险和低风险亚组(中位年龄为2.4年,而3.0年为中值,对数秩检验p 0.001)。在一个测试数据集和两个独立的数据集中,该9-lncRNA签名对预后同样有效。进一步的分析表明,签名的预测能力与临床变量无关,包括年龄,ER状态,ESR1状态和ERBB2状态。我们的结果表明,lncRNA标记可能是预测乳腺癌患者转移风险的有用的预后标志物,并可能有助于我们了解乳腺癌转移的分子机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号